HALO Halozyme Therapeutics Inc

$71.82

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.

Website: https://halozyme.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1159036
Address
11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA, US
Valuation
Market Cap
$7.26B
P/E Ratio
17.14
PEG Ratio
-2.50
Price to Book
19.96
Performance
EPS
$3.43
Dividend Yield
—
Profit Margin
43.70%
ROE
198.40%
Technicals
50D MA
$60.34
200D MA
$55.83
52W High
$66.00
52W Low
$37.97
Fundamentals
Shares Outstanding
124M
Target Price
$68.12
Beta
1.32

HALO EPS Estimates vs Actual

● Estimated
● Actual

HALO News & Sentiment

Aug 18, 2025 • Zacks Commentary BULLISH
Is Janus Henderson Small Cap Growth Alpha ETF ( JSML ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Aug 15, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Should Janus Henderson Small Cap Growth Alpha ETF ( JSML ) Be on Your Investing Radar?
Style Box ETF report for ...
Aug 11, 2025 • Zacks Commentary BULLISH
Why Halozyme Therapeutics ( HALO ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Aug 08, 2025 • Zacks Commentary SOMEWHAT-BULLISH
After Golden Cross, Halozyme Therapeutics ( HALO ) 's Technical Outlook is Bright
Is it a good or bad thing when a stock experiences a golden cross technical event?
Aug 08, 2025 • Zacks Commentary BULLISH
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Aug 07, 2025 • Benzinga SOMEWHAT-BULLISH
What Does the Market Think About Halozyme Therapeutics? - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics's HALO short percent of float has fallen 5.58% since its last report. The company recently reported that it has 9.60 million shares sold short, which is 10.67% of all regular shares that are available for trading.
Sentiment Snapshot

Average Sentiment Score:

0.262
50 articles with scored sentiment

Overall Sentiment:

Bullish

HALO Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.97
  • Whisper: —
  • Surprise %: 0.0%
Feb 18, 2025
Dec 31, 2024 (Pre market)
0.1 Surprise
  • Reported EPS: $1.26
  • Estimate: $1.16
  • Whisper: —
  • Surprise %: 8.7%
Oct 31, 2024
Sep 30, 2024 (Post market)
0.29 Surprise
  • Reported EPS: $1.27
  • Estimate: $0.98
  • Whisper: —
  • Surprise %: 29.6%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.15 Surprise
  • Reported EPS: $0.91
  • Estimate: $0.76
  • Whisper: —
  • Surprise %: 19.7%
May 07, 2024
Mar 31, 2024 (Post market)
0.09 Surprise
  • Reported EPS: $0.79
  • Estimate: $0.70
  • Whisper: —
  • Surprise %: 12.9%
Feb 20, 2024
Dec 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $0.82
  • Estimate: $0.83
  • Whisper: —
  • Surprise %: -1.2%
Nov 06, 2023
Sep 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $0.75
  • Estimate: $0.71
  • Whisper: —
  • Surprise %: 5.6%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.11 Surprise
  • Reported EPS: $0.74
  • Estimate: $0.63
  • Whisper: —
  • Surprise %: 17.5%
May 09, 2023
Mar 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $0.47
  • Estimate: $0.48
  • Whisper: —
  • Surprise %: -2.1%

Financials